Broker sees vet business as hidden value driver at Pets at Home

Pets at Home reported full-year group consumer revenue up 1% to £1.98 billion, but adjusted pre-tax profit fell roughly 30% to £93 million. Shore Capital says the market is overly focused on weakness in the retail business and is undervaluing the higher-margin veterinary division, highlighting a growing divergence in the company’s operating mix.

Analysis

The market is likely over-penalizing Pets at Home as if this were a broad consumer downturn, when the more important story is mix shift. If the higher-margin vet arm is still compounding while retail merely stagnates, the earnings base is being reset upward over a longer horizon even if near-term group profits look ugly. That creates a classic valuation trap: investors anchor on headline profit compression and miss that the quality of earnings is moving in the opposite direction.

Second-order winners are likely the larger vet consolidators and any adjacent services businesses that can capture share from fragmented independents. A weak retail backdrop can actually help the vet flywheel if it pushes more traffic into the ecosystem and increases customer lifetime value, while also pressuring smaller pet retailers with less ability to subsidize loyalty offers. Suppliers to discretionary pet consumables may face margin squeeze, but premium food and prescription categories should remain more resilient than the headline retail numbers imply.

The key risk is timing: this is a months-long re-rating story, not a quick catalyst. If consumers continue to trade down or defer non-essential pet spend, the market may keep discounting the retail drag and give no credit for vet resilience until another results cycle confirms the mix improvement. The contrarian read is that the stock may already be pricing the retail bear case aggressively enough; if vet growth merely stays mid-single digits and retail stabilizes, the earnings multiple can expand before absolute profits recover.

Watch for any sign that vet economics are normalizing faster than expected, because that would force a sentiment reset. Conversely, another quarter of retail weakness without vet acceleration would keep the stock in the penalty box and delay any rerating. The asymmetry favors entering only after confirmation that the market is still extrapolating the wrong business line.

Key Decisions for Investors

• Consider a medium-horizon long in PETS on weakness if management commentary suggests vet margins remain intact; target a 12-18 month rerating rather than near-term earnings recovery. Risk/reward is attractive if the market continues to value the company on low-quality retail earnings alone.
• Pair trade: long PETS / short a more retail-exposed pet discretionary name or UK consumer discretionary basket over 3-6 months. The thesis is that the vet mix should insulate PETS relative to pure retail peers if consumer spend remains soft.
• If available, buy call spreads on PETS with 6-12 month expiry to express a rerating view while capping downside. Use strikes around current levels to monetize any shift in narrative toward the veterinary segment.
• Avoid chasing the stock immediately after headline weakness; wait for a confirmation point in the next trading update or interim commentary. The trade works only if the market begins to value the vet division as the dominant earnings engine.